Kevin Ballinger has served as a director on the Board since September 2024. From July 2020 to September 2023, Mr. Ballinger served as Chief Executive Officer of Aldevron, LLC, a privately held genomics company that was acquired by Danaher Corporation in August 2021. Prior to joining Aldevron, Mr. Ballinger spent 25 years at Boston Scientific Corporation. During his last nine years at Boston Scientific, Mr. Ballinger served as Executive Vice President and Global President of the Interventional Cardiology division. Mr. Ballinger previously served on the boards of directors of Silk Road Medical, Inc. and Shockwave Medical, Inc. Mr. Ballinger earned his B.S. in mechanical engineering from Michigan Technological University, and his M.B.A. from the University of Minnesota s Carlson School of Management. The Board believes that Mr. Ballinger s experience in the medical device industry, as an executive leader, and as a member of the boards of directors of multiple companies in the healthcare industry qualifies him to serve as a director on the Board.